KEGG   DRUG: Natalizumab
Entry
D06886                      Drug                                   
Name
Natalizumab (USAN/INN);
Natalizumab (genetical recombination) (JAN);
Tysabri (TN)
Product
Sequence
(Heavy chain)
QVQLVQSGAE VKKPGASVKV SCKASGFNIK DTYIHWVRQA PGQRLEWMGR IDPANGYTKY
DPKFQGRVTI TADTSASTAY MELSSLRSED TAVYYCAREG YYGNYGVYAM DYWGQGTLVT
VSSASTKGPS VFPLAPCSRS TSESTAALGC LVKDYFPEPV TVSWNSGALT SGVHTFPAVL
QSSGLYSLSS VVTVPSSSLG TKTYTCNVDH KPSNTKVDKR VESKYGPPCP SCPAPEFLGG
PSVFLFPPKP KDTLMISRTP EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQFN
STYRVVSVLT VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ VYTLPPSQEE
MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SRLTVDKSRW
QEGNVFSCSV MHEALHNHYT QKSLSLSLGK
(Light chain)
DIQMTQSPSS LSASVGDRVT ITCKTSQDIN KYMAWYQQTP GKAPRLLIHY TSALQPGIPS
RFSGSGSGRD YTFTISSLQP EDIATYYCLQ YDNLWTFGQG TKVEIKRTVA APSVFIFPPS
DEQLKSGTAS VVCLLNNFYP REAKVQWKVD NALQSGNSQE SVTEQDSKDS TYSLSSTLTL
SKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC
(Disulfide bridge: H22-H96, H137-L213, H150-H206, H229-H'229, H232-H'232, H264-H324, H370-H428, H'22-H'96, H'137-L'213, H'150-H'206, H'264-H'324, H'370-H'428, L23-L-88, L133-L193, L'23-L'88, L'133-L'193)
  Type
Peptide
Remark
Therapeutic category: 1190
ATC code: L04AG03
Product: D06886<JP/US>
Efficacy
Immunosuppressant, Anti-integrin alpha 4 antibody
  Disease
Multiple sclerosis [DS:H01490]
Crohn's disease [DS:H00286]
  Type
Monoclonal antibody
Target
ITGA4 (CD49D) [HSA:3676] [KO:K06483]
  Pathway
hsa04512  ECM-receptor interaction
hsa04670  Leukocyte transendothelial migration
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AG Monoclonal antibodies
     L04AG03 Natalizumab
      D06886  Natalizumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Central Nervous System Agents
  Multiple Sclerosis Agents
   Natalizumab
    D06886  Natalizumab (USAN/INN)
 Immunological Agents
  Immunological Agents, Other
   Selective Adhesion-Molecule Inhibitor
    Natalizumab
     D06886  Natalizumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 1  Agents affecting nervous system and sensory organs
  11  Agents affecting central nervous system
   119  Miscellaneous
    1190  Miscellaneous
     D06886  Natalizumab (USAN/INN); Natalizumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Cell adhesion molecules: other families
   Integrins
    ITGA4 (CD49D)
     D06886  Natalizumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D06886
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D06886
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D06886
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D06886
Other DBs
CAS: 189261-10-7
PubChem: 49661786
NIKKAJI: J2.128.102F
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system